Interview with Pavel Chistyakov, General Manager, Pierre Fabre Russia
You were responsible for merging Pierre Fabre’s activities in Russia in 2008, and heading the new legal entity and 100% subsidiary. What is it like to set up a new…
Address: 119435 г.Москва, Саввинская набережная, д. 11,Russia
Tel: +7 (495) 789 9533
Web: http://www.pierre-fabre-Russia.ru/
Today, almost half a century since its founding, the Pierre Fabre Group is the second largest private pharmaceutical company in France and has market presence in over 140 countries around the world. Business within the company’s Russian affiliate is beginning to evolve rapidly. In 1993, the first drug produced by Pierre Fabre appeared on the Russian market. In 1999, the Group began selling skin care products through its exclusive distributor. In 2008, the decision was made to merge all areas in Russia, and in 2009, the company opened a 100% Russian subsidiary. In May 2009, the first skin care products were delivered to the affiliate from France, and in 2010, the first dental products were delivered.
In Russia, the main activity of LLC Pierre Fabre is the promotion of skin cosmetics, which are divided in two areas: dermatology and aesthetic skin care.
Pierre Fabre’s skin care products are sold exclusively in pharmacies.
Dermo-cosmetics and pharmaceutical products
You were responsible for merging Pierre Fabre’s activities in Russia in 2008, and heading the new legal entity and 100% subsidiary. What is it like to set up a new…
You founded this business in 2003, and it has since grown to encompass five offices and over 250 experts. Can you tell our readers a bit about the history behind…
The following is an interview with Dr. Smirnov, as well as Dr. Dmitri Pavlovich, Director, Clinical Operations Russia Quintiles very recently announced the launch of its first commercial project in…
The following is an interview with Dr. Pavlovich, as well as Dr. Sergey Smirnov, Director, Business Development and Operations, CEE, CIS and Russia Quintiles very recently announced the launch of…
GSK CEO Andrew Witty has said that GSK must move away from selling “white pills in Western markets” in order to offset widespread generic erosion. This means diversifying the company’s…
The following is joint interview of Mr. Vayntrub and Regina Karymova, General Manager of Invar Mr. Vayntrub, you founded Invar in 1991, and began to capitalize on foreign investment in…
Pepeliaev, Goltsblat & Partners and the major UK firm Berwin Leighton Paisner (BLP). It calls itself the first international Russian law firm. Can you explain to our readers the rationale…
You have lead this company since its beginnings in 2003, when it acquired ICN pharmaceuticals. In 2007, Pharmstandard carried out an IPO of 43% of its shares. How has the…
You were working for GSK since 2003 before joining Galderma this year. Some within the industry might view Galderma as a step down from the third-ranked pharmaceutical company in the…
Janssen recently signed memorandums of understanding with both the Skolkovo Foundation and ChemRar. Can you describe the strategic parameters and intended outcomes of these agreements? How do they factor into…
Mr. Demidov, you are one of the pioneers of market research studies in Russia. There is a quote you like to use: ‘Market research is a business in the United…
How would you describe CMS’s own presence in the life sciences field in Russia, and what unique competitive advantages does the firm bring to this area of practice? Over the…
With the announcement of the Pharma 2020 strategy to develop the domestic pharmaceutical industry, multinational companies have pledged an excess of $1Bn in investment into local infrastructure. Servier, however, preempted…
See our Cookie Privacy Policy Here